An open science pathway for drug marketing authorization—Registered drug approval

医学 临床试验 销售授权 批准的药物 家庭医学 临床研究 替代医学 药品 药理学 生物信息学 生物 病理
作者
Florian Naudet,Maximilian Siebert,Rémy Boussageon,Ioana A. Cristea,Erick H. Turner
出处
期刊:PLOS Medicine [Public Library of Science]
卷期号:18 (8): e1003726-e1003726 被引量:49
标识
DOI:10.1371/journal.pmed.1003726
摘要

ackgroundBefore drug approval, health authorities like the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) evaluate findings from the relevant clinical trials to assess the balance between clinical benefit and safety.When requesting marketing authorization for their drug products, pharmaceutical companies are allowed to choose the indication, design the trials, and choose assessments.In the US, pharmaceutical companies and drug manufacturers must submit full trial protocols to the FDA before those trials can begin.In Europe, companies can, at their discretion, obtain prior scientific advice from the EMA.This consultative process between sponsor and regulator is not fit for purpose, as there is, in practice, no clear a priori consensus on the exact criteria that will be applied to adjudicate success.Although the FDA lays out a set of a priori rules, all too often, it later bends those rules post hoc.For instance, for esketamine, for treatment of resistant depression, the FDA decided post hoc that a maintenance trial could substitute for a second positive short-term trial [1].OAU : Pleaseche ther examples include nalmefene for alcohol use disorder (approved by the EMA), which was based on a post hoc subgroup analysis of the pivotal trials [2], or eteplirsen for muscular dystrophy (approved by the FDA) despite a lack of clinical evidence [3].Even the initial standards agreed upon between the sponsor and regulator can be too lax.Too often, trials ask the wrong question: Trials may explore superiority over an inappropriately weak comparator such as placebo when superiority versus an already approved active comparator would be more clinically relevant [4].Trials can also be underpowered [4], focus on surrogate markers, or omit clinically relevant outcomes [5].Moreover, the regulator is laissez-faire with respect to trial publication in journal articles, allowing the sponsor to freely choose which findings to include and how to frame them, often diverging starkly from the

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
忧虑的乐驹完成签到 ,获得积分10
刚刚
mengmenglv完成签到 ,获得积分0
1秒前
Y_完成签到,获得积分10
1秒前
AAA完成签到,获得积分10
2秒前
Lucas完成签到,获得积分10
2秒前
yikeky星完成签到 ,获得积分10
3秒前
灰灰小猫完成签到,获得积分10
3秒前
AAA完成签到,获得积分10
4秒前
5秒前
yhyhyhyh完成签到,获得积分10
5秒前
CharlieYue完成签到,获得积分10
5秒前
胖大墨和黑大朵完成签到,获得积分10
6秒前
臻灏完成签到,获得积分10
6秒前
向沛山完成签到 ,获得积分10
7秒前
大胆的马里奥完成签到 ,获得积分10
8秒前
8秒前
学习使我快乐完成签到,获得积分10
8秒前
啦啦啦~完成签到,获得积分10
9秒前
淳于安筠完成签到 ,获得积分10
10秒前
小知了完成签到,获得积分10
12秒前
健壮问兰完成签到 ,获得积分10
12秒前
muxc完成签到,获得积分10
12秒前
Zhuideal完成签到,获得积分10
14秒前
菊花茶完成签到,获得积分10
15秒前
kveen完成签到,获得积分10
18秒前
紫熊发布了新的文献求助10
19秒前
耍酷的小白菜完成签到,获得积分10
19秒前
gcl完成签到,获得积分10
22秒前
程程完成签到,获得积分10
22秒前
宋相甫完成签到,获得积分10
25秒前
上杉绘梨衣完成签到,获得积分10
26秒前
激情的毛豆完成签到,获得积分10
27秒前
whj完成签到 ,获得积分10
27秒前
耍酷鼠标完成签到 ,获得积分0
28秒前
liu完成签到,获得积分10
29秒前
29秒前
蓝景轩辕完成签到 ,获得积分0
30秒前
lhl完成签到,获得积分10
30秒前
俏皮的数据线完成签到 ,获得积分10
30秒前
鬼笔环肽完成签到,获得积分10
31秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159131
求助须知:如何正确求助?哪些是违规求助? 9554607
关于积分的说明 21719828
捐赠科研通 7748795
什么是DOI,文献DOI怎么找? 3427149
关于科研通互助平台的介绍 2552079
邀请新用户注册赠送积分活动 2471428